{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T02:05:34Z","timestamp":1781316334950,"version":"3.54.1"},"reference-count":46,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Patients with chronic lymphocytic leukemia (CLL) refractory to covalent BTK and BCL2 inhibitors have a new unmet clinical need. Standard treatment options are able to obtain only limited and short-lasting disease control associated with reduced overall survival, and thus these patients have become ideal candidates for enrollment in clinical trials. Favorable results have been obtained with the use of noncovalent BTK inhibitors (roughly 70% overall response rate regardless of the actual resistance or intolerance to previous covalent BTK inhibitors) and anti-CD19 chimeric antigen receptor (CAR) T-cell therapy (with complete responses in up to 45% of cases and an undetectable measurable residual disease rate of 65% in the bone marrow). These 2 approaches should be considered valid options in this setting, although not yet approved. For young fit patients achieving remissions with salvage treatments, the option of allogeneic stem cell transplantation should be discussed as the outcome appears to be unaffected by number and type of previous targeted agents. Novel treatment strategies interfering with different mechanisms of CLL cell survival and proliferation are warranted, including small molecules with novel targets (eg, CDK9, MCL1, ERK inhibitors), CAR T cells targeting different antigens, CAR natural killer cells, or bispecific antibodies.<\/jats:p>","DOI":"10.1182\/hematology.2022000344","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T16:10:20Z","timestamp":1670602220000},"page":"316-322","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Novel therapies and combinations in CLL refractory to BTK inhibitors and venetoclax"],"prefix":"10.1182","volume":"2022","author":[{"given":"Lydia","family":"Scarf\u00f2","sequence":"first","affiliation":[{"name":"1 Universit\u00e0 Vita-Salute San Raffaele, Milano, Italy"},{"name":"2 IRCCS Ospedale San Raffaele, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"10","key":"2022121313281640700_hem2022000344C1","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.3324\/haematol.2018.205930","article-title":"Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"104","author":"Steurer","year":"2019","journal-title":"Haematologica"},{"issue":"16","key":"2022121313281640700_hem2022000344C2","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1200\/JCO.18.01460","article-title":"Final results of a randomized, phase III study of rituximab with or without idelalisib followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia","volume":"37","author":"Sharman","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"2022121313281640700_hem2022000344C3","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1097\/CCO.0000000000000585","article-title":"The evolving treatment landscape of chronic lymphocytic leukemia","volume":"31","author":"Schiattone","year":"2019","journal-title":"Curr Opin Oncol"},{"issue":"1","key":"2022121313281640700_hem2022000344C4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann Oncol"},{"issue":"4","key":"2022121313281640700_hem2022000344C5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1158\/1078-0432.CCR-21-1237","article-title":"Recognizing unmet need in the era of targeted therapy for CLL\/SLL: \"What's past is prologue\" (Shakespeare)","volume":"28","author":"Mato","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2022121313281640700_hem2022000344C6","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3324\/haematol.2017.182907","article-title":"Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"issue":"12","key":"2022121313281640700_hem2022000344C7","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.3324\/haematol.2016.147900","article-title":"Ibrutinib for relapsed\/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients","volume":"101","author":"UK CLL Forum","year":"2016","journal-title":"Haematologica"},{"issue":"14","key":"2022121313281640700_hem2022000344C8","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1158\/1078-0432.CCR-19-3815","article-title":"Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy","volume":"26","author":"Mato","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2022121313281640700_hem2022000344C9","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.3324\/haematol.2018.193615","article-title":"Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States","volume":"103","author":"Mato","year":"2018","journal-title":"Haematologica"},{"issue":"9","key":"2022121313281640700_hem2022000344C10","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.3324\/haematol.2020.272500","article-title":"Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"106","author":"Rogers","year":"2021","journal-title":"Haematologica"},{"issue":"9","key":"2022121313281640700_hem2022000344C11","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/bloodadvances.2018030007","article-title":"Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib","volume":"3","author":"Awan","year":"2019","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2022121313281640700_hem2022000344C12","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2021-148544","article-title":"Phase 2 study of zanubrutinib in BTK inhibitor-intolerant patients (pts) with relapsed\/refractory B-cell malignancies","volume":"138","author":"Shadman","year":"2021","journal-title":"Blood"},{"issue":"suppl 3","key":"2022121313281640700_hem2022000344C13","first-page":"1890","article-title":"Zanubrutinib in acalabrutinib- intolerant patients (pts) with B-cell malignancies","volume":"6","author":"Shadman","year":"2022","journal-title":"HemaSphere"},{"issue":"3","key":"2022121313281640700_hem2022000344C14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/17474086.2018.1435268","article-title":"Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?","volume":"11","author":"Lampson","year":"2018","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"2022121313281640700_hem2022000344C15","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1182\/blood.2021015132","article-title":"Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib- and acalabrutinib-treated patients","volume":"140","author":"Black","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2022121313281640700_hem2022000344C16","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1182\/blood-2019-125488","article-title":"BTK Leu528Trp\u2014a potential secondary resistance mechanism specific for patients with chronic lymphocytic leukemia treated with the next generation BTK inhibitor zanubrutinib","volume":"134","author":"Handunnetti","year":"2019","journal-title":"Blood"},{"issue":"3","key":"2022121313281640700_hem2022000344C17","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov"},{"issue":"4","key":"2022121313281640700_hem2022000344C18","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ccell.2019.08.005","article-title":"Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies","volume":"36","author":"Gui\u00e8ze","year":"2019","journal-title":"Cancer Cell"},{"key":"2022121313281640700_hem2022000344C19","article-title":"Single-cell multiomics reveal the scale of multi-layered adaptations enabling CLL relapse during venetoclax therapy [published online ahead of print 16 June 2022]","author":"Thijssen","journal-title":"Blood"},{"key":"2022121313281640700_hem2022000344C20","article-title":"Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies [published online ahead of print 15 June 2022]","author":"Thomalla","journal-title":"Blood"},{"issue":"suppl 3","key":"2022121313281640700_hem2022000344C21","first-page":"668","article-title":"Acalabrutinib vs rituximab plus idelalisib or bendamustine in relapsed\/refractory chronic lymphocytic leukemia: ASCEND results at ~4years of follow-up","volume":"6","author":"Ghia","year":"2022","journal-title":"HemaSphere"},{"issue":"10277","key":"2022121313281640700_hem2022000344C22","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"issue":"suppl 3","key":"2022121313281640700_hem2022000344C23","first-page":"147","article-title":"Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated CLL\/SLL: updated results from the phase 1\/2 BRUIN study","volume":"6","author":"Mato","year":"2022","journal-title":"HemaSphere"},{"issue":"suppl 3","key":"2022121313281640700_hem2022000344C24","first-page":"682","article-title":"Nemtabrutinib (MK-1026), a non-covalent inhibitor of wild-type and C481S mutated Bruton tyrosine kinase for B-cell malignancies: efficacy and safety of the phase 2 dose expansion BELLWAWE-001 study","volume":"6","author":"Woyach","year":"2022","journal-title":"HemaSphere"},{"issue":"8","key":"2022121313281640700_hem2022000344C25","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"issue":"7897","key":"2022121313281640700_hem2022000344C26","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","article-title":"Decade-long leukaemia remissions with persistence of CD4+ CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"issue":"12","key":"2022121313281640700_hem2022000344C27","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1182\/blood.2021011895","article-title":"Phase 1 Transcend Cll 004 study of lisocabtagene maraleucel in patients with relapsed\/refractory CLL or SLL","volume":"139","author":"Siddiqi","year":"2022","journal-title":"Blood"},{"issue":"26","key":"2022121313281640700_hem2022000344C28","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","article-title":"Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib","volume":"35","author":"Turtle","year":"2017","journal-title":"J Clin Oncol"},{"issue":"303","key":"2022121313281640700_hem2022000344C29","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"issue":"19","key":"2022121313281640700_hem2022000344C30","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood.2019002936","article-title":"Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure","volume":"135","author":"Gauthier","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2022121313281640700_hem2022000344C31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-140622","article-title":"Transcend CLL 004: phase 1 cohort of lisocabtagene maraleucel (liso-cel) in combination with ibrutinib for patients with relapsed\/refractory (R\/R) chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL)","volume":"136","author":"Wierda","year":"2020","journal-title":"Blood"},{"issue":"17","key":"2022121313281640700_hem2022000344C32","doi-asserted-by":"crossref","first-page":"4113","DOI":"10.1182\/bloodadvances.2020002184","article-title":"Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia","volume":"4","author":"Kim","year":"2020","journal-title":"Blood Adv"},{"issue":"16","key":"2022121313281640700_hem2022000344C33","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1182\/bloodadvances.2020001956","article-title":"Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents","volume":"4","author":"Roeker","year":"2020","journal-title":"Blood Adv"},{"issue":"suppl 3","key":"2022121313281640700_hem2022000344C34","first-page":"687","article-title":"A phase 1 study with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with B-cell malignancies: preliminary data","volume":"6","author":"Opat","year":"2022","journal-title":"HemaSphere"},{"issue":"suppl 3","key":"2022121313281640700_hem2022000344C35","first-page":"683","article-title":"A first-in-human phase 1 study of oral loxo-338, a selective BCL2 inhibitor, in patients with advanced hematologic malignancies (trial in progress)","volume":"6","author":"Jurczak","year":"2022","journal-title":"HemaSphere"},{"issue":"suppl 1","key":"2022121313281640700_hem2022000344C36","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1182\/blood-2021-152811","article-title":"Trial in progress: phase 1b study of lisaftoclax (APG-2575) as a single agent or combined with other therapeutic agents in patients with relapsed and\/or refractory chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (R\/R CLL\/SLL)","volume":"138","author":"Davids","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2022121313281640700_hem2022000344C37","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1182\/blood-2021-146563","article-title":"Subcutaneous epcoritamab in patients with relapsed\/refractory chronic lymphocytic leukemia: preliminary results from the Epcore CLL-1 trial","volume":"138","author":"Kater","year":"2021","journal-title":"Blood"},{"issue":"suppl 3","key":"2022121313281640700_hem2022000344C38","first-page":"686","article-title":"A phase 1 first in-human study of BGB-16673, a Bruton tyrosine kinase protein degrader, in patients (pts) with B-cell malignancies (trial in progress)","volume":"6","author":"Tam","year":"2022","journal-title":"HemaSphere"},{"issue":"6","key":"2022121313281640700_hem2022000344C39","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"2022121313281640700_hem2022000344C40","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bjh.18357","article-title":"Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia","volume":"199","author":"Hampel","year":"2022","journal-title":"Br J Haematol"},{"issue":"17","key":"2022121313281640700_hem2022000344C41","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1182\/bloodadvances.2022007708","article-title":"Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes","volume":"6","author":"Hyak","year":"2022","journal-title":"Blood Adv"},{"issue":"20","key":"2022121313281640700_hem2022000344C42","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1182\/bloodadvances.2021005083","article-title":"Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition","volume":"5","author":"Lew","year":"2021","journal-title":"Blood Adv"},{"issue":"suppl 3","key":"2022121313281640700_hem2022000344C43","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/01.HS9.0000845560.07338.2d","article-title":"Fixed-duration (FD) ibrutinib + venetoclax for first-line treatment of chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL): 3-year follow-up from the phase 2 Captivate Study FD Cohort","volume":"6","author":"Moreno","year":"2022","journal-title":"HemaSphere"},{"issue":"suppl 3","key":"2022121313281640700_hem2022000344C44","first-page":"100","article-title":"Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 5year results of the randomized CLL14 study","volume":"6","author":"Al-Sawaf","year":"2022","journal-title":"HemaSphere"},{"issue":"8","key":"2022121313281640700_hem2022000344C45","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.2021015014","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2022121313281640700_hem2022000344C46","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3324\/haematol.2021.280061","article-title":"Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies","volume":"107","author":"Allan","year":"2022","journal-title":"Haematologica"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/316\/2023055\/316scarfo.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/316\/2023055\/316scarfo.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T13:28:55Z","timestamp":1670938135000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2022\/1\/316\/493549\/Novel-therapies-and-combinations-in-CLL-refractory"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,9]]},"published-print":{"date-parts":[[2022,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2022000344","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,9]]},"published":{"date-parts":[[2022,12,9]]}}}